Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM PRESERVATIVE FREE.
DICUMAROL vs HEPARIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Heparin binds to antithrombin III (ATIII), causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, as well as factors IXa, XIa, and XIIa. This inhibits clot formation and propagation.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
Initial bolus of 80 units/kg IV, followed by continuous infusion at 18 units/kg/hour IV; adjusted to maintain aPTT of 1.5-2.5 times control.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Terminal half-life is 0.5–2.5 hours (mean ~1.5 h) after IV administration; dose-dependent due to saturable clearance. At therapeutic doses, half-life averages 1–2 hours.
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Primarily renal; small amounts in urine as unchanged drug and metabolites. Biliary/fecal elimination is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant